Takeda's Approved Blood Cancer Drug Hits Primary Goal In Newly-Diagnosed Patient Settings
Takeda's Approved Blood Cancer Drug Hits Primary Goal In Newly-Diagnosed Patient Settings
武田批准的血癌藥物在新診斷的患者環境中達到主要目標
- Takeda Pharmaceutical Co Ltd's (NYSE:TAK) Phase 3 PhALLCON trial of Iclusig (ponatinib) met its primary endpoint in newly-diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) patients.
- The study demonstrated that Iclusig plus reduced-intensity chemotherapy achieved higher rates of minimal residual disease (MRD)-complete negative remission (CR) compared to imatinib.
- In the trial, no new safety signals were observed.
- Related: Takeda Seeks FDA Approval For Hereditary Angioedema Treatment For Younger Kids.
- In September, Puma Biotechnology Inc (NASDAQ:PBYI) announced an agreement to license the worldwide research and development and commercial rights to Takeda's alisertib for cancer indications.
- Alisertib has been tested in metastatic cancers, including breast cancer, small cell lung cancer, head and neck cancer, ovarian cancer, peripheral T cell lymphoma, and acute myeloid leukemia.
- Price Action: TAK shares are up 1.13% at $13.93 on the last check Thursday.
- Photo Via Company
- 武田製藥株式會社Iclusig(Ponatinib)的(紐約證券交易所市場代碼：TAK)第3階段PhALLCON試驗在新診斷的費城染色體陽性急性淋巴細胞白血病(Ph+ALL)患者中達到了主要終點。
- 研究表明，與伊馬替尼相比，Iclusig加低強度化療獲得了更高的微小殘留病(MRD)-完全陰性緩解(CR)率。
- 在試驗中，沒有觀察到新的安全信號。
- 相關：武田尋求FDA批准對年幼兒童的遺傳性血管性水腫治療.
- 在9月份，彪馬生物技術公司納斯達克(代號：PBYI)宣佈達成一項協議，將授權武田的alisertib用於癌症適應症的全球研發和商業權。
- Alisertib已經在轉移性癌症中進行了測試，包括乳腺癌、小細胞肺癌、頭頸癌、卵巢癌、外周T細胞淋巴瘤和急性髓系白血病。
- 價格行動：德意志銀行股價週四尾盤上漲1.13%，至13.93美元。
- 照片通過公司
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。